LOS ANGELE Auriga Laboratories, a specialty pharmaceutical company, has signed a license agreement with Outlook Pharmaceuticals.
According to Monday’s press release, Auriga will have the exclusive rights to market and sell a new product indicated for the treatment of Attention Deficit Hyperactivity Disorder. The new product combines one of the most frequently prescribed drug classes for this condition, in a unique dosage form previously not available to patients.
ADHD treatments are one of the most frequently prescribed products in the United States, the company said, citing that there are over 35 million prescriptions written by physicians, which generating estimated sales of over $3.5 billion dollars in the country each year.
The product is expected to be approved by the Food and Drug Administration in early 2008 and launch during the second quarter of 2008.
“This Agreement solidifies Auriga’s commitment to enhance our product portfolio with products approved using the ANDA and 505(b)(2) NDA regulatory pathways,” said Philip Pesin, chief executive officer of Auriga.